Femoral Versus Nonfemoral Peripheral Access for Transcatheter Aortic Valve Replacement

Beurtheret, Sylvain; Karam, Nicole; Resseguier, Noémie; Houël, Rémi; Modine, Thomas; Folliguet, Thierry; Chamandi, Chekrallah; Com, Olivier; Gélisse, Richard; Billé, Jacques; Joly, Patrick; Barra, Nicolas; Tavildari, Alain; Commeau, Philippe; Armero, Sébastien; Pankert, Mathieu; Pansiéri, Michel; Siame, Sabrina; Köning, René; Laskar, Marc; Dolley, Yvan Le; Maudière, A; Villette, Bertrand; Khanoyan, Patrick; Seitz, Julien; Blanchard, Didier; Spaulding, Christian; Lefèvre, Thierry; Belle, Éric Van; Gilard, Martine; Eltchaninoff, Hélène; Iung, Bernard; Verhoye, Jean Philippe; Akar, Ramzi Abi; Achouh, Paul; Cuisset, Thomas; Leprince, Pascal; Marijon, Éloi; Breton, Hervé; Lafont, Antoine

doi:10.1016/j.jacc.2019.09.054

Cited by 91 publications

(82 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in recent registries, there was a lower incidence of atrial fibrillation (3.2 vs. 19%), bleeding (4.3 vs. 19.9%), acute renal failure (0 vs. 12.1%), and shorter time of hospitalization (6 vs. 8 days) in the TC-TAVI group [8]. Data from the French TAVI Registry of 21611 patients, including 914 with TC-TAVI shows the safety of TC access [33]. The safety of carotid artery access with no excess of 30-days mortality was also confirmed in the analysis of 11033 patients between 2013-2015 in France.…”

Section: Discussionmentioning

confidence: 93%

Comparison of the short-term safety and efficacy of transcarotid and transfemoral access routes for transcatheter aortic valve implantation

Hudziak¹,

Wojakowski²,

Malinowski³

et al. 2021

Kardiol Pol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

Comparison of the short-term safety and efficacy of transcarotid and transfemoral access routes for transcatheter aortic valve implantation

Hudziak¹,

Wojakowski²,

Malinowski³

et al. 2021

Kardiol Pol

View full text Add to dashboard Cite

show abstract

“…Alternative modes of access include transthoracic access (direct aortic and transapical) and non-femoral peripheral access (transaxillary, transcarotid, and transcaval). Patients who lack TF access are more likely to be obese men with peripheral arterial disease [ 56 ]. All modes of alternative access have been associated with higher mortality and stroke compared to TF patients with markedly worse outcomes for transapical, direct aortic, and transcaval patients [ 57 – 63 ].…”

Section: Anatomic Factors Favoring Savrmentioning

confidence: 99%

Expansion of TAVR into Low-Risk Patients and Who to Consider for SAVR

et al. 2020

View full text Add to dashboard Cite

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe aortic stenosis (AS) over the last decade. The results of the Placement of Aortic Transcatheter Valves (PARTNER) 3 and Evolut Low Risk trials demonstrated the safety and efficacy of TAVR in low-surgical-risk patients and led to the approval of TAVR for use across the risk spectrum. Heart teams around the world will now be faced with evaluating a deluge of younger, healthier patients with severe AS. Prior to the PARTNER 3 and Evolut Low Risk studies, this heterogenous patient population would have undergone surgical aortic valve replacement (SAVR). It is unlikely that TAVR will completely supplant SAVR for the treatment of severe AS in patients with a low surgical risk, as SAVR has excellent short- and long-term outcomes and years of durability data. In this review, we outline the critical role that SAVR will continue to play in the treatment of severe AS in the post-PARTNER 3/Evolut Low Risk era.

show abstract

“…The TC and TS approaches are associated with similar mortality. In the few studies that have reported outcomes for TCv access, short-and long-term mortality as well as adverse event rates are higher than those described for other alternative approaches in large registries (1). The TCv approach is still experimental and should only be performed in patients with favorable abdominal vasculature who are ineligible for TF and other alternate peripheral accesses.…”

mentioning

confidence: 97%

“…The proportion of patients undergoing TAVR by transthoracic alternate access has decreased over the last decade, while the use of peripheral access has remained relatively constant (1). In Europe, data from the French Aortic National CoreValve and Edwards 2 (FRANCE 2) and FRANCE transcatheter aortic valve implantation registries show that alternate access use decreased by >50% over the last decade (1). In North America, the Society of Thoracic Surgeons/American College of Cardiology/ Transcatheter Valve Therapy (STS/ACC/TVT) registry shows that the use of alternate access decreased from 24.1% to 13.4% between 2012 and 2015 (2).…”

mentioning

confidence: 99%